EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION. - Wikidata - wikimedia - TriplyDB

EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

http://www.wikidata.org/entity/Q30490419

about

Intravitreal anti-VEGF agents, oral glucocorticoids, and laser photocoagulation combination therapy for macular edema secondary to retinal vein occlusion: preliminary report.The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.

P2860

Q55275094-6A3754D6-F749-4482-A550-83AF5A78DA09 Q55413465-74DFDF78-EC31-4D23-B40F-BDD042E3DCBE

P2860

EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

http://www.wikidata.org/entity/Q30490419

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@ast

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@en

type

label

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@ast

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@en

prefLabel

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@ast

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@en

P1433

Q30490419-283312B5-E0F1-43FC-B8D6-7E4ACE49C7E6

P1476

Q30490419-93920D6E-CBCB-4274-8907-DACBBFCA98CB

P2093

Q30490419-1557EB36-6A56-4223-BEE9-AC9A806E05AF

Q30490419-22F84118-08C0-4A01-8C79-B00D5568DA1F

Q30490419-3E766C29-C04D-4F2D-B417-D301BB6F4CA1

Q30490419-67664F89-C6CB-411C-BC0C-9448E4DE7BC9

Q30490419-9BAA14C1-F12E-44E1-99A8-2919F75C4CB8

Q30490419-ADCF4F2D-4B8A-4318-A5E5-02E08002A314

Q30490419-C6564628-E734-436B-B33F-725C9E760824

Q30490419-C84C9322-697C-40BD-8AEC-17C691DFBEF0

Q30490419-E957665C-36E5-42A6-996B-A199293529B2

Q30490419-FD3633FB-19E6-475B-89C6-D61F5AA412B2

P2860

Q30490419-1811B375-B1AE-4287-9DCA-21FD7BE28A35

Q30490419-3D0044DB-9C9F-4EC1-9762-AC787961C9CC

Q30490419-4A0E09A2-A09B-47AE-BA12-D648DB27F844

Q30490419-4D1D505C-E9A2-4E62-8F8C-CC2CAE611528

Q30490419-6D41E276-4F24-4653-A91B-DF3E28A3B6BA

Q30490419-71C190D6-5C33-48E9-9416-251B2B7E4ED0

Q30490419-74A82CC0-42AF-4809-A02F-E4C2A6EEEC93

Q30490419-7F91786B-3834-43BC-A7F5-5B6DE1D90245

Q30490419-80CD876C-06BD-40F4-8007-DB83C0113E3E

Q30490419-A906FB6E-25F8-45D2-B31A-C74BFA74E2EA

P304

Q30490419-BDB3D104-F109-41B6-BA3D-F711130C3505

P31

Q30490419-D5E67AD2-C4FF-415E-B452-21AA1F1C3D46

P356

Q30490419-71B569BB-0656-4776-B3D9-FE5818122B42

P433

Q30490419-6D7EBD78-767C-4C62-B96E-3718286E6E97

P478

Q30490419-C57BDCEF-BA87-444B-BC0B-23DF4AF0FA68

P577

Q30490419-03C69B24-916E-47FB-B81B-4DD408694AD2

P698

Q30490419-EA085D61-9D75-4F32-AC45-3AB1F5A33436

P932

Q30490419-269D8E52-75F8-4512-B449-57AE10352F07

P356

IAE.0000000000001404

P1433

P1476

EFFICACY AND SAFETY OF INTRAVI ...... ARY TO RETINAL VEIN OCCLUSION.

@en

P2093

Bing Lin

http://www.w3.org/2001/XMLSchema#string

Feng Zhang

http://www.w3.org/2001/XMLSchema#string

Haiying Zhou

http://www.w3.org/2001/XMLSchema#string

Quan Wu

http://www.w3.org/2001/XMLSchema#string

Shanshan Tao

http://www.w3.org/2001/XMLSchema#string

Xiaoling Liu

http://www.w3.org/2001/XMLSchema#string

Xuan Jiao

http://www.w3.org/2001/XMLSchema#string

Yingdong Luo

http://www.w3.org/2001/XMLSchema#string

Zuhua Sun

http://www.w3.org/2001/XMLSchema#string

Zunhong Ke

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.

Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects

Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.

Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion.

P304

1723-1730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IAE.0000000000001404

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27893623

http://www.w3.org/2001/XMLSchema#string

P932

5598918

http://www.w3.org/2001/XMLSchema#string